SAN MARINO, Calif., Oct. 18 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on "The Advent of Pathotropic Medicine for Cancer" at the Global Pharma R&D Summit 2007 to be held in Boston MA. On October 22, 2007 at 8:00 a.m., Dr. Hall will present the scientific principles, the clinical validation, and global development status of the company's innovative pathotropic (disease-seeking) -- targeting technology embodied in its lead product, Rexin-G, the first pathotropically targeted genetic medicine developed for the treatment of advanced-stage and metastatic cancer.
(LOGO 72dpi: Send2Press.com/mediaboom/logo-epeius_72dpi.jpg)
The Global Pharma R&D Summit 2007 (http://www.globalpharmasummit.com), which will be held at the Boston Marriott Hotel, Newton MA 02466 USA, on October 22-23, 2007, showcases cutting-edge biotechnology and pharmaceutical companies that are developing superior technologies and products in healthcare and healthcare related areas, and offers a forum to meet with suppliers, service providers, opinion leaders, and representatives from other leading pharmaceutical and biotechnology companies worldwide. The Keynote Address provides an opportunity for Epeius to update the industry in regard to its recent clinical developments and global partnering initiatives to expedite the international development of Rexin-G, which is currently in clinical trials in Europe, Japan, and ASEAN member countries, as well as the United States.
The focus on Epeius Biotechnologies during National Breast Cancer
Awareness Month, is apropos-for the company has just opened an Advanced
Phase I/II trial for chemo-resistant breast cancer in San Marino and Santa
Monica California. Rexin-G, has received Orphan Drug Status from the FDA
based on unp
|SOURCE Epeius Biotechnologies|
Copyright©2007 PR Newswire.
All rights reserved